ALXN2050
Sponsors
Alexion Pharmaceuticals, Inc.
Conditions
Generalized Myasthenia GravisHealthyIgANImmunoglobulin A NephropathyImpaired Hepatic FunctionLNLupus NephritisMyasthenia Gravis
Phase 1
Study of ALXN2050 in Participants With Renal Impairment
CompletedNCT04623710
Start: 2021-07-08End: 2022-03-21Updated: 2023-09-29
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
CompletedNCT04660890
Start: 2020-12-12End: 2021-03-16Updated: 2021-12-29
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
CompletedNCT04933682
Start: 2021-06-23End: 2021-08-04Updated: 2022-12-08
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
CompletedNCT04952545
Start: 2021-07-09End: 2021-09-07Updated: 2022-12-09
A Study of Single-dose ALXN2050 in Healthy Adults
CompletedNCT05047458
Start: 2017-11-28End: 2018-04-13Updated: 2021-09-17
A Study of Multiple Doses of ALXN2050 in Healthy Adults
CompletedNCT05047484
Start: 2019-01-07End: 2019-07-23Updated: 2021-09-17
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
CompletedNCT05202145
Start: 2022-01-11End: 2022-03-21Updated: 2023-04-04
Study of ALXN2050 in Participants With Hepatic Impairment
TerminatedNCT05259085
Start: 2022-04-07End: 2024-08-12Updated: 2025-03-19
Phase 2
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
TerminatedNCT04170023
Start: 2019-12-16End: 2024-03-20Updated: 2024-11-20
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
TerminatedNCT05097989
Start: 2022-01-14End: 2024-12-09Updated: 2025-10-15
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
TerminatedNCT05218096
Start: 2022-04-27End: 2024-04-03Updated: 2025-01-09